Table 5.
Patient demographics for the matched cohort vs patients experiencing PASC related conditions
| Case (COVID PCR (+)) with PASCa | Total case (COVID PCR (+)) | Control (COVID PCR (-)) with PASCb | Total control (COVID PCR (-)) | |
|---|---|---|---|---|
| Total, n (%) | ||||
| Total | 4625 (100.0%) | 28,118 (100.0%) | 9745 (100.0%) | 70,293 (100.0%) |
| Sex, n (%) | ||||
| Female | 2866 (62.0%) | 15,993 (56.9%) | 6092 (62.5%) | 40,396 (57.5%) |
| Male | 1759 (38.0%) | 12,125 (43.1%) | 3653 (37.5%) | 29,897 (42.5%) |
| Age in years, n (%) | ||||
| 18–29 | 866 (18.7%) | 5791 (20.6%) | 1985 (20.4%) | 14,805 (21.1%) |
| 30–39 | 899 (19.4%) | 5624 (20.0%) | 1898 (19.5%) | 14,028 (20.0%) |
| 40–49 | 810 (17.5%) | 5352 (19.0%) | 1695 (17.4%) | 12,828 (18.2%) |
| 50–64 | 1355 (29.3%) | 7948 (28.3%) | 2693 (27.6%) | 19,543 (27.8%) |
| 65–74 | 480 (10.4%) | 2449 (8.7%) | 1018 (10.4%) | 6516 (9.3%) |
| 75–84 | 178 (3.8%) | 775 (2.8%) | 363 (3.7%) | 2109 (3.0%) |
| 85+ | 37 (0.8%) | 179 (0.6%) | 93 (1.0%) | 464 (0.7%) |
| Race/Ethnicity (self-reported), n (%) | ||||
| Asian | 465 (10.1%) | 3018 (10.7%) | 977 (10.0%) | 7772 (11.1%) |
| Black | 1903 (41.1%) | 11,402 (40.6%) | 4266 (43.8%) | 29,680 (42.2%) |
| Hispanic | 1189 (25.7%) | 6877 (24.5%) | 2012 (20.6%) | 14,057 (20.0%) |
| White | 877 (19.0%) | 5325 (18.9%) | 2041 (20.9%) | 14,963 (21.3%) |
| Unknown | 191 (4.1%) | 1496 (5.3%) | 449 (4.6%) | 3821 (5.4%) |
| Service area, n (%) | ||||
| Baltimore | 907 (19.6%) | 5199 (18.5%) | 1987 (20.4%) | 13,177 (18.7%) |
| DC and Southern Maryland | 2127 (46.0%) | 13,337 (47.4%) | 4536 (46.5%) | 33,247 (47.3%) |
| Northern Virginia | 1590 (34.4%) | 9578 (34.1%) | 3222 (33.1%) | 23,861 (33.9%) |
| Unknown | 1 (0.0%) | 4 (0.0%) | 0 (0.0%) | 8 (0.0%) |
| BMI, n (%) | ||||
| <18.5 (Underweight) | 22 (0.5%) | 146 (0.5%) | 85 (0.9%) | 597 (0.8%) |
| 18.5–24.9 (Healthy Weight) | 601 (13.0%) | 3750 (13.3%) | 1639 (16.8%) | 12,179 (17.3%) |
| 25–29.9 (Overweight) | 1043 (22.6%) | 6454 (23.0%) | 2331 (23.9%) | 16,680 (23.7%) |
| 30–39.9 (Obesity) | 1418 (30.7%) | 7956 (28.3%) | 2624 (26.9%) | 17,916 (25.5%) |
| 40 + (Severe Obesity) | 468 (10.1%) | 2325 (8.3%) | 802 (8.2%) | 4781 (6.8%) |
| No Result | 1073 (23.2%) | 7487 (26.6%) | 2264 (23.2%) | 18,140 (25.8%) |
| Co-morbidities, n (%) | ||||
| Chronic Kidney Disease | 179 (3.9%) | 849 (3.0%) | 402 (4.1%) | 2285 (3.3%) |
| COPD | 45 (1.0%) | 266 (0.9%) | 182 (1.9%) | 935 (1.3%) |
| Diabetes Mellitus | 981 (21.2%) | 5271 (18.7%) | 1756 (18.0%) | 11,498 (16.4%) |
| Hepatitis B | 31 (0.7%) | 200 (0.7%) | 75 (0.8%) | 532 (0.8%) |
| HIV | 50 (1.1%) | 239 (0.8%) | 92 (0.9%) | 567 (0.8%) |
| Pregnancy | 126 (2.7%) | 489 (1.7%) | 310 (3.2%) | 1486 (2.1%) |
| Malignancy | 140 (3.0%) | 729 (2.6%) | 485 (5.0%) | 2598 (3.7%) |
| Hospitalizationc, n (%) | ||||
| Hospitalization | 239 (5.2%) | 511 (1.8%) | 665 (6.8%) | 1366 (1.9%) |
| Death Post Indexd, n (%) | ||||
| Death | 8 (0.2%) | 42 (0.1%) | 30 (0.3%) | 58 (0.1%) |
aCOVID PCR( + ) patients that experienced at least one PASC related condition in the acute and persistent and/or late periods. bCOVID PCR(-) patients that experienced at least one PASC related condition in the acute and persistent and/or late periods. cHospitalization represents if a patient was hospitalized in the 30–120-time period post index date. dDeath represents if a patient died in the 0-120 days post index.